The Adjuvant Paclitaxel and Trastuzumab (APT) trial evaluated small (≤2 cm), node‐negative, HER2+ breast cancers treated with up‐front surgery followed by adjuvant taxane and trastuzumab‐based therapy, demonstrating disease‐specific survival of 93% at 7‐years.24 The gene discussed is ERBB2; the disease is breast carcinoma.